Barbara Obrien, DO
Adult Medicine · Ellisville, MONPI 1437211794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Pfizer at 32.9% of the total.
Across 82 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$362
- AbbVie$189
- Novo Nordisk$97
- Boehringer Ingelheim$63
- Arbor Pharmaceuticals, Inc.$52
- Abbott$41
- plus $297 from 13 others
What the payments were for
- Food & beverage$1,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 36 | $362 |
| AbbVie | 12 | $189 |
| Novo Nordisk | 6 | $97 |
| Boehringer Ingelheim | 4 | $63 |
| Arbor Pharmaceuticals, Inc. | 4 | $52 |
| Abbott | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $40 |
| GSK | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Shire North American Group Inc | 2 | $29 |
| Globus Medical | 1 | $27 |
| Johnson & Johnson | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
How this compares
Too few adult medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 112 | $138,117 |
| OzempicSemaglutide | 110 | $127,406 |
| EliquisApixaban | 64 | $62,771 |
| XareltoRivaroxaban | 34 | $42,400 |
| JardianceEmpagliflozin | 42 | $42,332 |
| RybelsusSemaglutide | 15 | $27,659 |
| ViberziEluxadoline | 11 | $17,129 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 66 | $16,446 |
| Repatha SureclickEvolocumab | 17 | $14,510 |
| MyrbetriqMirabegron | 13 | $10,496 |
| Duloxetine Hcl | 188 | $4,822 |
| PremarinEstrogens, Conjugated | 12 | $4,672 |
| SynthroidLevothyroxine Sodium | 39 | $4,615 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,155 |
| Atorvastatin Calcium | 351 | $3,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $97 | $155,065125 claims |
| Lilly USA, LLCMounjaro | $16 | $138,117112 claims |
| PfizerEliquis, Premarin | $362 | $67,44376 claims |
| Johnson & JohnsonXarelto | $20 | $42,40034 claims |
| Boehringer IngelheimJardiance | $63 | $42,33242 claims |
| AbbVieViberzi, Synthroid | $189 | $21,74450 claims |
| GSKArexvy | $34 | $16,44666 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Missourion file to place this against a meaningful peer group, so we don't.
Other adult medicine in Ellisville
- Stefan ScheidlerKennett$5K
- Shelly HouseIndependence$959
- Azalie ArmknechtBranson$866
- Lauren RileyBlue Springs$815
- Michael ColeSaint Louis$317
- Madhuri SubbaiahSaint Louis$296
- Samuel EvansWest Plains$248
- David RyanTrenton$239
- Mahrukh KhanSt. Louis$238
- Eduard RasputkovKirksville$214
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.